ONTX - オンコノバ・セラピュ―ティクス (Onconova Therapeutics Inc.) オンコノバ・セラピュ―ティクス

 ONTXのチャート


 ONTXの企業情報

symbol ONTx
会社名 Onconova Therapeutics Inc (オンコノバ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 オンコノヴァ・セラピューティクス(Onconova Therapeutics Inc.)は臨床段階のバイオ医薬品会社であり、がん治療用の小分子薬剤候補の発見・開発に取り組む。同社が作成した標的抗がん剤は、がんを促進する特定の細胞経路に対して機能するように設計される。同社は3つの臨床段階の製品候補と6つの前臨床プログラムを有する。同社の前臨床パイプラインはキナーゼ、細胞代謝や分裂を標的にする6つのプログラムを含む。   オンコノバ・セラピュ―ティクスは米国のバイオテクノロジ―会社。がん治療の小分子医薬品候補の発見と開発に従事する。主に臨床期向け治療薬の開発に注力。臨床検査段階の治療薬候補には、骨髄異形成症候群および頭頚部がん用の「リゴサチブ」、急性放射線症候群用の「recilisib」などがある。   Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
本社所在地 375 Pheasant Run Newtown PA 18940 USA
代表者氏名 Michael M. B Hoffman マイケル・M・ホフマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 267-759-3681
設立年月日 36130
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数 36人
url www.onconova.com
nasdaq_url https://www.nasdaq.com/symbol/ontx
adr_tso
EBITDA EBITDA(百万ドル) -24.34600
終値(lastsale) 5.92
時価総額(marketcap) 33590944.32
時価総額 時価総額(百万ドル) 33.76100
売上高 売上高(百万ドル) 1.30200
企業価値(EV) 企業価値(EV)(百万ドル) 4.22100
当期純利益 当期純利益(百万ドル) -22.85700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Onconova Therapeutics Inc revenues increased 96% to $1M. Net loss decreased 12% to $9.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income net increase from $11K to $112K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$22.78 to -$6.14.

 ONTXのテクニカル分析


 ONTXのニュース

   Recessive Dystrophic Epidermolysis Market Dynamic Expansion in Clinical Research with Phoenix Tissue Repair, Onconova Therapeutics, Fibrocell Technologies, Holostem Terapie Avanzate, Wings Therapeutics Inc.  2021/08/27 10:23:19 OpenPR
Recessive dystrophic epidermolysis bullosa severe generalized (RDEB-sev gen) is the classic form of the condition and is the most severe. Affected infants are typically born with widespread blistering and areas of missing skin, often caused by trauma that occurs during
   Onconova Therapeutics EPS beats by $0.01, beats on revenue  2021/08/12 20:07:21 Seeking Alpha
   Bright Stock Buzz: Sunworks, Inc. (NASDAQ:SUNW), Onconova Therapeutics, Inc. (NASDAQ:ONTX)  2021/08/09 21:49:55 Stock Equity
Sunworks, Inc. (SUNW) with the stream of 7.17% also noticed, India Onconova Therapeutics, Inc. (ONTX) encountered a rapid change of 2.34% in the last hour of Mondays trading session. Sunworks, The post Bright Stock Buzz: Sunworks, Inc. (NASDAQ:SUNW), Onconova Therapeutics, Inc. (NASDAQ:ONTX) appeared first on Stocks Equity .
   Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021  2021/08/05 12:00:00 Intrado Digital Media
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12. Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.
   Hillcrest Wealth Advisors - NY, LLC Buys iShares Core S&P Small-Cap ETF, iShares MSCI ...  2021/08/03 16:38:28 GuruFocus
Related Stocks: GOOGL , XLF , AAPL , IJR , EEM , BND , MSFT , GOOG , 0T2 , BA , JNK , FB , XLU , ONTX , D ,
   Volatile Stock to Watch- Onconova Therapeutics, Inc. (NASDAQ:ONTX) encountered the change of -4.29%  2021/06/10 22:00:28 Stock Equity
On Thursday, Shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) reached at $7.14 price level during last trade its distance from 20 days simple moving average was -13.67%, and its distance from The post Volatile Stock to Watch- Onconova Therapeutics, Inc. (NASDAQ:ONTX) encountered the change of -4.29% appeared first on Stocks Equity .
   Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?  2021/06/10 12:30:00 Benzinga
NEW YORK , June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.
   Analysts Are Bullish on Top Healthcare Stocks: Onconova Therapeutics (ONTX), AB Science SA (ABSCF)  2021/06/10 12:15:12 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Onconova Therapeutics (ONTX) and AB The post Analysts Are Bullish on Top Healthcare Stocks: Onconova Therapeutics (ONTX), AB Science SA (ABSCF) appeared first on Smarter Analyst .
   Onconova Therapeutics surges 17% but still in negative territory year to date  2021/06/09 17:35:29 Seeking Alpha
   Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital  2021/06/03 00:00:00 BioSpace
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.
   Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday  2021/03/17 15:23:04 Benzinga
bluebird bio, Inc. (NASDAQ: BLUE ), Onconova Therapeutics, Inc. (NASDAQ: ONTX ), FSD Pharma Inc. (NASDAQ: HUGE ) and Immatics N.V. (NASDAQ: IMTX ) are among the biggest biopharma movers in Wednesday's session. Executive Exodus At Bluebird Bio: Bluebird Bio has seen a couple of high-profile departures recently amid a setback in its gene therapy program for sickle cell disease. The company revealed in a filing that Chief Medical Officer David Davidson has left as of Tuesday. Davidson, however, will continue as a consultant for a period of six months to provide guidance and support for the biopharma's late-stage programs in severe genetic disease, the company said. Earlier this week, Joanne Smith-Farrell, who served as COO and business unit head for oncology at bluebird bio, jumped ship to assume the role of CEO at privately held Be Biopharma. Watch "Biotech Buzz" on Benzinga's YouTube channel. Onconova Spikes On Reddit Interest: Shares of … Full story available on Benzinga.com
   Tanger Factory Outlet Centers : Thinking about buying stock in Tanger Factory Outlet Centers, Onconova Therapeutics, Cinedigm, Cigna Corp, or Anthem? | MarketScreener  2021/03/04 16:00:09 MarketScreener
NEW YORK, March 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SKT, ONTX, CIDM, CI, and ANTM. … | March 4, 2021
   Onconova Therapeutics : Schedule 14A | MarketScreener  2021/02/26 23:43:05 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy… | February 26, 2021
   Onconova Therapeutics: ON12330 And Inhibition Of CDK4/6 And ARK5 In Breast Cancer  2021/02/19 20:04:31 Seeking Alpha
Overview of Onconova Therapeutics, including pipeline, balance sheet, and recent bullish stock price action. Review of breast cancer and focus on HR+ HER 2- metastatic breast cancer.
   Global Polo-Like Kinase 1 (PLK1) Inhibitor Pipeline Insight Report 2021: Key players Involved are Oncoheroes Biosciences, Cyclacel, Cardiff Oncology, Onconova Therapeutics, & Sentinel oncology - ResearchAndMarkets.com  2021/02/19 10:28:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment

 関連キーワード  (医薬品 米国株 オンコノバ・セラピュ―ティクス ONTX Onconova Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)